SCHEMBL360218

SCHEMBL360218

Nc1nc2cc(Br)c(F)cc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.53
GFER P55789 1/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
ALDH1A1 P00352 3/20 0.52
CYP3A4 P08684 3/20 0.52
TP53 P04637 2/20 0.52
TSHR P16473 1/20 0.52
LMNA P02545 3/20 0.49
ILK Q13418 1/20 0.46
SCN4A P35499 3/20 0.45
EPHX2 P34913 1/20 0.45
RAB9A P51151 5/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DRD2 P14416 2/20 0.44
NPC1 O15118 4/20 0.41
CYP1A2 P05177 2/20 0.41
PKM P14618 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4071678 0.93 AXL (0.53) AXLGFERSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL210148 0.84 AXL (0.60) AXLGFERSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL31132414 0.84 SMN1; SMN2 (0.59) AXLGFERSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL29801372 0.84 AXL (0.60) AXLGFERSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL8379624 0.84 SMN1; SMN2 (0.59) AXLGFERSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL3660199 0.79 ILK (0.40) AXLGFERSMN1; SMN2ALDH1A1TP53
SCHEMBL19709633 0.78 ILK (0.40) AXLGFERSMN1; SMN2ALDH1A1TP53
SCHEMBL19709634 0.78 AXL (0.53) AXLGFERSMN1; SMN2ALDH1A1CYP3A4
SCHEMBL21604553 0.78 SMN1; SMN2 (0.59) SMN1; SMN2ALDH1A1TP53LMNAILK
SCHEMBL1638626 0.78 AXL (0.53) AXLGFERSMN1; SMN2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597370-B2 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-24 US disclosed
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2019-05-16 US disclosed
US-20170260178-A1 ANTIBACTERIAL COMPOUNDS SPERO GYRASE INC (US) 2017-09-14 US disclosed
EP-2828257-B1 ANTIBACTERIAL COMPOUNDS BIOTA EUROPE LTD (GB) 2017-07-26 EP disclosed
US-9604976-B2 Antibacterial compounds SPERO GYRASE, INC. (US) 2017-03-28 US disclosed
US-20150329530-A1 ANTIBACTERIAL COMPUNDS SPERO GYRASE, INC. 2015-11-19 US disclosed
EP-2828257-A1 ANTIBACTERIAL COMPOUNDS Biota Europe Ltd (GB) 2015-01-28 EP disclosed
US-8906902-B2 Antibacterial compounds BIOTA EUROPE LIMITED (GB) 2014-12-09 US disclosed
WO-2013138860-A1 ANTIBACTERIAL COMPOUNDS BIOTA EUROPE LIMITED (GB) 2013-09-26 WO disclosed
US-20130252938-A1 Antibacterial Compounds BIOTA EUROPE LTD. (GB) 2013-09-26 US disclosed
US-8299065-B2 Antibacterial condensed thiazoles BIOTA EUROPE LTD. (GB) 2012-10-30 US disclosed
US-8299065-B2 Antibacterial condensed thiazoles BIOTA EUROPE LTD. (GB) 2012-10-30 US disclosed
US-8299065-B2 Antibacterial condensed thiazoles BIOTA EUROPE LTD. (GB) 2012-10-30 US disclosed
WO-2012007510-A1 COMPOUNDS FOR BINDING AND IMAGING AMYLOID PLAQUES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-01-19 WO disclosed
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2010-12-02 US disclosed
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2010-12-02 US disclosed
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2010-12-02 US disclosed
EP-2231653-A1 ANTIBACTERIAL CONDENSED THIAZOLES Biota Europe Ltd (GB) 2010-09-29 EP disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 WO disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260178-A1 ANTIBACTERIAL COMPOUNDS STS, PGLS, PEPD AXL 2055/4885GFER 1102/4885SMN1; SMN2 4614/4885
US-20150329530-A1 ANTIBACTERIAL COMPUNDS STS, PEPD, PGLS AXL 3833/4885GFER 1253/4885SMN1; SMN2 4323/4885
US-20190144403-A1 2-(BENZOTHIAZOL-2-YL)-2-CYANO-ACETAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIAL LIPASE INHIBITORS LIPG, LPL, CEL AXL 2332/4885GFER 2093/4885SMN1; SMN2 4636/4885
US-20130252938-A1 Antibacterial Compounds STS, PGLS, PEPD AXL 2055/4885GFER 1102/4885SMN1; SMN2 4614/4885
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES NEK6, NEK1, TXK AXL 2795/4885GFER 1293/4885SMN1; SMN2 3360/4885
US-10597370-B2 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors LIPG, LPL, CEL AXL 2332/4885GFER 2093/4885SMN1; SMN2 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.